Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  Pharnext  /  Forum Pharnext geopend

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharnext PSE:ALPHA.FR, FR001400N1P4

  • 0,158 16 apr 2024 17:35
  • -0,016 (-9,43%) Dagrange 0,158 - 0,180
  • 23.756 Gem. (3M) 32,4M

Forum Pharnext geopend

214 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 11 »» | Laatste | Omlaag ↓
  1. forum rang 4 holenbeer 4 september 2019 23:45
    quote:

    Kelewan schreef op 4 september 2019 09:33:

    [...]

    Ja, eerst op 8,90, laatste op 5,78. Zo van, ergens komt de ommekeer wel, toch blij dat dat gebeurt voor je moet bijkopen tot je een belang moet melden ;).

    Als ik een belang zou moeten melden zou ik dat helemaal niet erg vinden :-)
  2. ReBa 9 september 2019 08:32
    Pharnext and Galapagos successfully achieved their research and development collaboration
    PARIS, France, 8:00 am, September 9, 2019 (CET) – Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomics data and artificial intelligence, today announced the successful completion of its research and development collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a late-stage clinical biotechnology company specialized in the discovery and development of small molecule medicines with novel mechanisms of action.
    The collaboration aims to generate a new drug development pipeline in several therapeutic areas for Galapagos, including immunoinflammatory disorders. Namely, the collaboration was focused on the identification of:
    • Additional therapeutic indications for Galapagos’ clinical drug candidates,
    • Novel candidates for combinations with Galapagos’ current portfolio of drug candidates, and
    • New therapeutic targets in indications pre-defined by Galapagos.
    Together, Pharnext and Galapagos have met their objectives.
    Leveraging its innovative PLEOTHERAPYTM platform, Pharnext successfully identified additional therapeutic indications for Galapagos’ candidate drugs. Combining Galapagos’ expertise in holistic pharmaceutical development with Pharnext’s cutting-edge approach, several of these new indications were further prioritized for experimental validation studies in animal models, in which Galapagos’ candidate drugs demonstrated efficacy.
    Pharnext’s PLEOTHERAPYTM platform also identified multiple approved drugs to combine with Galapagos’ candidate drugs in order to create a more potent effect in these selected indications. Some combinations of Galapagos’ candidate drugs with Pharnext’s identified drugs have already shown a superior effect in relevant animal models.
    Finally, Pharnext’s PLEOTHERAPYTM platform identified new targets in therapeutic indications that Galapagos had prioritized initially, supporting Galapagos’ research and development activities in these indications.
    “These results reaffirm the robustness of Pharnext’s development of combination drugs and validate its application to potentially any therapeutic area. Pharnext’s innovative approach bolsters the disease treatment path,” said Professor Daniel Cohen, MD, PhD, Co-Founder and Chief Executive Officer of Pharnext. “We are proud to collaborate with Galapagos to generate new treatment options for patients.”
    “We want to thank Pharnext for the rewarding collaboration, which has led to the identification of interesting novel combinations that are now in advanced preclinical testing,” said Piet Wigerinck, PhD, Chief Scientific Officer of Galapagos.
    This collaboration aims to expand the market of these novel combinations to new indications. Generating new patents should increase the value of these new compounds.
  4. ReBa 9 september 2019 10:31
    Dat denk ik niet. Als je dat er uit opmaakt, dan zou ik het bericht en de eerdere berichten maar nog een keer lezen.

    Er staat dat Pharnext samen met Galapagos op meerdere gebieden vooruitgang heeft geboekt.

    In het persbericht bij aanvang wordt o.a. Onno van de Stolpe geciteerd en daarbij staat ook dat het intellectuele eigendom een gezamenlijk eigendom is.

    Onno van de Stolpe, Chief Executive Officer van Galapagos voegde eraan toe: “Pharnext heeft al veelbelovende klinische resultaten verkregen met zijn geavanceerde technologie, wat ons heeft aangemoedigd om samen te werken. We zijn er erg blij mee samen te werken met Pharnext en profiteren van Pharnext's expertise in het ontcijferen van de moleculaire netwerken van ziekten.
    We hopen dat dit de R & D-mogelijkheden van Galapagos zal versterken om op een zeer efficiënte en moderne manier nieuwe therapeutische benaderingen te genereren. "
    Intellectuele eigendom met betrekking tot synergetische geneesmiddelencombinaties gegenereerd door de R & D-samenwerking zal gezamenlijk eigendom zijn van Pharnext en Galapagos.
  5. forum rang 10 DeZwarteRidder 9 september 2019 10:40
    quote:

    ReBa schreef op 9 september 2019 10:31:

    Dat denk ik niet. Als je dat er uit opmaakt, dan zou ik het bericht en de eerdere berichten maar nog een keer lezen.

    Er staat dat Pharnext samen met Galapagos op meerdere gebieden vooruitgang heeft geboekt.

    In het persbericht bij aanvang wordt o.a. Onno van de Stolpe geciteerd en daarbij staat ook dat het intellectuele eigendom een gezamenlijk eigendom is.

    Onno van de Stolpe, Chief Executive Officer van Galapagos voegde eraan toe: “Pharnext heeft al veelbelovende klinische resultaten verkregen met zijn geavanceerde technologie, wat ons heeft aangemoedigd om samen te werken. We zijn er erg blij mee samen te werken met Pharnext en profiteren van Pharnext's expertise in het ontcijferen van de moleculaire netwerken van ziekten.
    We hopen dat dit de R & D-mogelijkheden van Galapagos zal versterken om op een zeer efficiënte en moderne manier nieuwe therapeutische benaderingen te genereren. "
    Intellectuele eigendom met betrekking tot synergetische geneesmiddelencombinaties gegenereerd door de R & D-samenwerking zal gezamenlijk eigendom zijn van Pharnext en Galapagos.
    Helaas levert dat niks op in de komende 10 à 20 jaar.
  6. ReBa 6 januari 2020 21:42
    Pharnext Announces Encouraging Data from Open-Label Phase 3
    Extension Study of PXT3003 in Charcot-Marie-Tooth Disease
    Type 1A (CMT1A)
    • Results suggestsustained safety and efficacy of PXT3003 in CMT1A patients after 25 months of total trial
    time (Phase 3 trial + open-label extension study)
    • CMT1A patients showed improvement or stabilization of disease as measured by the Overall
    Neuropathy Limitations Scale during the open-label Phase 3 extension study
    Conference call in English today at 10:30 p.m. CET (4:30 p.m. ET)
    Conference call in French on Tuesday January 7 at 10:00 a.m. CET (4:00 a.m. ET)
    PARIS, France, 07:00 p.m., January 6, 2020 (CET) – Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical
    company pioneering a new approach to developing innovative drug combinations based on big genomics data
    and artificial intelligence, today announced encouraging data from the open-label Phase 3 extension study of
    PXT3003 in patients with Charcot-Marie-Tooth Disease Type 1A (CMT1A).
    Data from 185 patients in the 9-month PLEO-CMT open-label extension study (PLEO-CMT-FU) were consistent
    with prior positive safety and tolerability results in the 15-month, double-blind Phase 3 study (PLEO-CMT).
    Highlights from a preliminary efficacy analysis1 of the open-label PLEO-CMT-FU study include:
    • Patients improved on the Overall Neuropathy Limitation Scale (ONLS) across all dose cohorts during
    the extension study as compared to the ONLS decline seen in the placebo group.
    • Patients treated with PXT3003 since the start of the Phase 3 program showed ONLS improvement or
    remained stable at the end of the PLEO-CMT-FU extension study as compared to the ONLS at the
    beginning of the PLEO-CMT study.
    • Patients with a decline in ONLS during their treatment interruption improved upon resuming
    treatment.
    “These data further reinforce our confidence in the safety and efficacy signals from the previous clinical
    studies,” said Daniel Cohen, M.D., Ph.D., co-founder and Chief Executive Officer of Pharnext. “We look forward
    to continuing our discussions with the U.S. Food and Drug Administration (FDA) and expect to align on the
    design of an additional pivotal Phase 3 trial in the first half of 2020, with the goal of initiating the study as soon
    as possible.”
    “Patients with CMT1A have no pharmacological treatment options for their chronic, progressive hereditary
    disease,” said Prof. Dr. med. Maggie C. Walter, M.A., Associate Professor of Neurology, Friedrich-BaurInstitute, Dept. of Neurology, Ludwig-Maximilians-University of Munich, Germany. “Although these data were
    generated from an open-labelstudy, the data seem to support the efficacy signal observed in the primary Phase
    3 trial and suggest potential sustained efficacy over the course of two years.”
    Prof. Florian P. Thomas, M.D., M.A., Ph.D., M.S., Founding Chair & Professor, Department of Neurology,
    Hackensack Meridian School of Medicine, Hackensack, NJ, USA, said: “These results provide further argument that PXT3003 could potentially stabilize and even improve neurological function in patients with CMT1A. I am
    excited by these results and the potential for PXT3003 to serve as a novel and safe therapeutic approach for
    CMT1A patients.”

    www.pharnext.com/images/2020.01.06_PX...
  7. [verwijderd] 23 maart 2020 09:15
    Pharnext Announces Identification of a Large Set of Frequently
    Prescribed Drugs to be Repurposed for Fighting COVID-19,
    Using its Pleotherapy™ Platform
    • A novel strategy to rapidly reposition drugs using existing COVID-19 clinical data
    • Methods, findings and proposals from Pharnext are available at Preprints.org
    (https://www.preprints.org/manuscript/202003.0302/v1) and awaiting peer review
    PARIS, France, 7:30am, March 23, 2020 (CET) – Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical
    company pioneering a new approach to developing innovative drug combinations based on big genomic data
    and artificial intelligence, today announced the identification of 97 frequently prescribed drugs as potential
    candidates to be repositioned for treating COVID-19 through the use of its Pleotherapy™ platform.
    In a pandemic emergency situation, the repurposing of already-known drugs is a method of choice prior to
    vaccine development. Various drug repositioning efforts are ongoing worldwide. However, the understanding
    of COVID-19, a disease that emerged less than four months ago, is highly limited. To respond to the urgency,
    especially as it may take up to a year before a vaccine is available to patients, Pharnext applied an original
    strategy based on its experience in complex disease mechanisms and bioinformatics methods in order to find
    drugs to modify the disease more immediately.
    Once a virus enters human cells, it utilizes the cellular machinery to its advantage, allowing the virus to
    proliferate within the human host. Pharnext’sstrategy was to evaluate which part of this machinery is affected
    by coronaviruses (e.g., COVID-19, SARS, MERS). This allowed the Company to identify already approved drugs
    for common diseases, which can also potentially impair the COVID-19-related viral process. In total, Pharnext
    identified 97 candidate drugs, most of which are not known to have antiviral activities. In addition, four of the
    drugs Pharnext identified using its methodology are already undergoing clinical trials for COVID-19, including
    chloroquine.
    A large group of the identified repositioning candidate drugs were originally developed and used for frequent
    medical conditions such as type 2 diabetes and hypertension. It happens that the individuals suffering from
    these diseases have some of the highest risks to evolve towards severe forms of COVID-19. This suggests,
    besides multiple potential reasons linking these pathologies and an outcome of COVID-19 infection, a
    biological link between these common diseases, sensitivity to COVID-19 and the drugs Pharnext hasidentified.
    Pharnext’s strategy of focusing on already approved drugs for common diseases as repositioning candidates
    (e.g., statins, anti-diabetic and anti-hypertensive drugs) results in two significant advantages:
    1. Quickly prioritizes the best candidates by comparing COVID-19 evolution among patients taking
    these drugs vs. patients not taking these drugs, through big data analysis of medical records(“real-
    world evidence” testing), to rapidly launch launch further confirmatory studies.
    2. Provide to the population: The rapid spread of the COVID-19 virus calls for a rapid response. Once
    proven effective, the top candidates could be made immediately available as they are already
    produced to treat common diseases.
    “Pharnext is dedicated to identifying potential drugs that may be repurposed to treat COVID-19,” said Daniel
    Cohen, M.D., Ph.D., co-founder and Chief Executive Officer of Pharnext.

    Groet, poil
  8. [verwijderd] 23 maart 2020 09:17
    which can be applied to any disease, Pharnext has conceived a method enabling a rapid drug repositioning to
    fight COVID-19. A coordinated international effort is urgently needed to mutualize i) comprehensive COVID-19
    patient data and ii) confined facilities suited for significant experimental testing. For the sake of patients and
    our communities, we hope that the biopharma community and health regulatory agencies worldwide can work
    together to find a way for ultra-fast approval tracks for these and other therapies.”
    Candidate drugs proposed by Pharnext need to be further tested for confirmation, as mono- or polytherapy,
    following two parallel processesfor an accelerated preclinical evaluation and clinical development: 1)standard
    preclinical disease models and 2) “real-world evidence” testing, whereby big data from medical records are
    used to compare COVID-19 patients, who are already taking these candidate drugs.
    1
    Hydroxychloroquine, Chloroquine and Azythromicine have generated encouraging results in clinical trials,
    which have also been identified by Pharnext’s approach.
    Pharnext is currently evaluating various options to validate its initial findings as well as to further advance the
    work towards a treatment for COVID-19 through various collaborations.
  20. [verwijderd] 26 maart 2020 13:02
    We need a Big Data effort to find a COVID-19 cure, says pioneering geneticist
    Famed French researcher Daniel Cohen, head of drug developer Pharnext, has a short list of 97 drugs that have been through some clinical testing that could play a role in a vaccine for COVID-19. To move things forward, the entire world needs to get together and share medical data on COVID-19 patients so the clues can be systematically studied.

    "I'm an optimist," says Daniel Cohen, a legendary French scientist, "If we can make this combined, coordinated effort, not just our laboratory, but all scientists working, worldwide, then, yes, I'm optimistic we can find a solution."

    From cancelled conferences to disrupted supply chains, not a corner of the global economy is immune to the spread of COVID-19.

    Cohen was talking about patients with COVID-19, the disease that results from the SARS-CoV2 virus, a disease that has engulfed the world's energy and attention.

    Cohen, 69, inaugurated the era of "Big Data" in the life sciences at the end of the 1980s, leading the effort then that produced the first "map" of the human genome.

    As with the human genome project, where world leaders joined with scientists to generate funds for laboratories that shared information, Cohen thinks the world needs to share patient data from COVID-19 on a massive scale, including symptoms, medical history, and drugs the patients are on.

    "We must have a coordinated effort to mutualize COVID-19 medical records, including records of all the medications being given to patients," said Cohen, "to analyze, with artificial intelligence tools, the influence, positive or negative, of their conditions, and their drugs, on this disease."

    Cohen spoke to ZDNet by phone on Sunday from Paris, where he is chief executive of development-stage drug maker Pharnext. The context was Cohen's announcement Monday that his Pharnext team has come up with 97 drugs that have been through various stages of clinical testing, that might play a role in an eventual vaccine for COVID-19.

    "Might" is the operative word. There is substantial complexity in the operation of the disease. It is widely known that primarily, but not exclusively, those dying are those who are older and who have "co-morbidities," pre-existing conditions that seem to become aggravated by the illness. The most prominent co-morbidities include hypertension, diabetes, cerebrovascular and cardiovascular diseases.

    There's a mystery as to why those conditions seem to make patients more susceptible. Is there an underlying "confounder," asks Cohen, a condition that produces both hypertension, say, and susceptibility to the virus.

    "Let's keep in mind that there are multiple potential other reasons for this comorbidity," says Cohen. "Organs from aged patients with diabetes or hypertension are often already damaged, therefore, COVID-19 might simply accelerate that degradation."

214 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 11 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!